Why the study?
Numerous real-world studies had compared NOACs with VKAs in non-valvular atrial fibrillation, motivating a meta-analysis to synthesize the available evidence.
Do NOACs reduce the risk of ischemic stroke and intracranial hemorrhage compared to VKAs in patients with non-valvular atrial fibrillation?
Do NOACs reduce the risk of ischemic stroke and intracranial hemorrhage compared to VKAs in patients with non-valvular atrial fibrillation?
This meta-analysis of real-world studies confirms that NOACs are as effective as VKAs for stroke prevention in NVAF while significantly reducing the risk of intracranial hemorrhage.
Answers are grounded in this paper and cite their sources.
NOACs appear at least as effective and safe as VKAs in real-world NVAF; reinforces RCT findings in observational data but should not yet change practice.
Introduction: Numerous real-world studies have compared non-vitamin K antagonist oral anticoagulants (NOACs) with vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF). A meta-analysis was performed to synthesize the available evidence.Methods: Systematic searches were performed through 12/2016 to identify non-randomized NVAF studies comparing NOACs with VKAs, and reporting effectiveness, safety, or persistence.Results: Of 562 citations identified, 49, 79, and 18 compared rivaroxaban, dabigatran, and apixaban, respectively, with VKAs and were included. Compared with VKAs, rivaroxaban was associated with a reduced risk of ischemic stroke (IS) (hazard ratio [HR] = 0.83, 95% confidence interval [CI] = 0.75–0.93), intracranial haemorrhage (ICH) (HR = 0.69, 95% CI = 0.52–0.90), and non-persistence (HR = 0.62, 95% CI = 0.60–0.65). Dabigatran was associated with a significantly lower risk of IS (HR = 0.80, 95% CI = 0.65–0.98) and ICH (HR = 0.45, 95% CI = 0.36–0.58), but not for non-persistence (HR = 0.91, 95% CI = 0.53–1.55), compared with VKAs. Apixaban was associated with a lower risk of ICH than VKAs (HR = 0.41, 95% CI = 0.28–0.60), but was not different to VKAs in terms of IS (HR = 1.01, 95% CI = 0.87–1.17) or non-persistence (HR = 1.08, 95% CI = 0.81–1.45).Conclusion: NOACs appear to be at least as effective and safe as VKAs for stroke prevention in patients with NVAF.
No takes yet. Share an insight, caveat, or question.
Coleman et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: